🔎 Trials Near Me

Hjem › Alpha-1-antitrypsinmangel › Ohio

Alpha-1-antitrypsinmangel kliniske forsøg i Ohio

3 studier for Alpha-1-antitrypsinmangel søger deltagere på steder i Ohio.

Byer i Ohio

Officiel studietekst (engelsk)

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

  • GC2501 Study Site 104, Cleveland
RekruttererFase 3
Alder 18 til 80 · Alle køn · Opdateret 11. aug. 2026 · NCT07555483

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

  • University Hospitals Cleveland Medical Center, Cleveland
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 13. maj 2026 · NCT05677971

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

  • University Hospitals Cleveland Medical Center, Cleveland
RekruttererFase 3
Alder 18 til 75 · Alle køn · Opdateret 5. mar. 2026 · NCT06165341

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.